Instructions:
Clinical and pharmacological groups
07.005 (Combined drug with antiprotozoal, antifungal and antibacterial effects) 06.021 (Antibiotic of the macrolide group - azalide)
pharmachologic effect
An antibiotic of the macrolide group, a representative of the azalides. Suppresses RNA-dependent protein synthesis of sensitive microorganisms.
Active against gram-positive bacteria: Staphylococcus aureus, Streptococcus spp. (including Streptococcus pneumoniae, Streptococcus pyogenes /group A/); gram-negative bacteria: Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus ducreyi, Moraxella catarrhalis, Escherichia coli, Bordetella pertussis, Bordetella parapertussis, Borrelia burgdorferi, Neisseria gonorrhoeae, Campylobacter spp., Legionella pneumophila; anaerobic bacteria: Bacteroides fragilis.
Azithromycin is also active against Chlamydia trachomatis, Mycoplasma pneumoniae, Mycoplasma hominis, Treponema pallidum.
Also active against Toxoplasma gondii.
Pharmacokinetics
Rapidly absorbed from the gastrointestinal tract. Eating reduces the absorption of azithromycin. Cmax in plasma is achieved after 2-3 hours. It is quickly distributed in tissues and biological fluids. 35% of azithromycin is metabolized in the liver by demethylation. More than 59% is excreted unchanged in bile, about 4.5% is excreted unchanged in urine.
Dosage
They are established individually, taking into account the nosological form, the severity of the disease and the sensitivity of the pathogen.
Adults orally - 0.25-1 g 1 time / day; children - 5-10 mg/kg 1 time/day. Duration of treatment is 2-5 days.
Drug interactions
When used simultaneously with ergot alkaloids, the risk of developing ergotism cannot be excluded.
With simultaneous use of azithromycin with warfarin, cases of increased effects of the latter have been described.
With the simultaneous use of digoxin or digitoxin with azithromycin, a significant increase in the concentration of cardiac glycosides in the blood plasma and the risk of developing glycoside intoxication are possible.
When used simultaneously with disopyramide, a case of the development of ventricular fibrillation has been described.
When used simultaneously with lovastatin, cases of rhabdomyolysis have been described.
When used simultaneously with rifabutin, the risk of developing neutropenia and leukopenia increases.
With simultaneous use, the metabolism of cyclosporine is disrupted, which increases the risk of developing side and toxic reactions caused by cyclosporine.
Use during pregnancy and lactation
Azithromycin penetrates the placental barrier. Use during pregnancy is possible only in cases where the expected benefit to the mother outweighs the potential risk to the fetus.
If it is necessary to use azithromycin during lactation, the issue of stopping breastfeeding should be decided.
Side effects
From the digestive system: nausea, vomiting, flatulence, diarrhea, abdominal pain, transient increase in the activity of liver enzymes; rarely - cholestatic jaundice.
Allergic reactions: rarely - skin rash, angioedema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Dermatological reactions: rarely - photosensitivity.
From the side of the central nervous system: dizziness, headache; rarely - drowsiness, weakness.
From the hematopoietic system: rarely - leukopenia, neutropenia, thrombocytopenia.
From the cardiovascular system: rarely - chest pain.
From the genitourinary system: vaginitis; rarely - candidiasis, nephritis, increased residual urea nitrogen.
Other: rarely - hyperglycemia, arthralgia.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to azithromycin, incl. bronchitis, pneumonia, skin and soft tissue infections, otitis media, sinusitis, pharyngitis, tonsillitis, gonorrheal and non-gonorrheal urethritis and/or cervicitis, Lyme disease (borreliosis).
Contraindications
Hypersensitivity to azithromycin and other macrolide antibiotics.
special instructions
Not recommended for use in patients with impaired liver function.
Use with caution in case of impaired renal function.
Azithromycin should be taken at least 1 hour before or 2 hours after meals or antacids.
Use for renal impairment
Use with caution in case of impaired renal function.
Use for liver dysfunction
Not recommended for use in patients with impaired liver function.
Preparations containing AZITHROMYCIN
• TREMAK-SANOVEL tab., coated. film-coated, 500 mg: 3 pcs. • ECOMED® (ECOMED) tab., coated. film coating, 500 mg: 3 pcs. • AZITHROMYCIN caps. 250 mg: 6 or 10 pcs. • AZITHRUS® powder for preparation. susp. d/orally 50 mg: pack. 3 or 6 pcs. included with or without a cup • AZITHROX caps. 500 mg: 3 pcs. • AZITHROMYCIN caps. 250 mg: 6 or 10 pcs. • SUMAMOX tab., coated. coated, 500 mg: 3 pcs. • AZIWOK caps. 250 mg: 6 pcs. • SUMAMOX granules for preparation. susp. for oral administration 100 mg/5 ml: vial. 50 ml • AZICID tab., coated. coated, 500 mg: 3 pcs. • SUMAMED® (SUMAMED®) lyophilisate for preparation. r-ra d/inf. 500 mg: fl. 5 pieces. • SUMAMED® tab., coated. film-coated, 500 mg: 3 pcs. • ZITHROCIN tab., coated. film-coated, 250 mg: 6 pcs. • ZI-FACTOR (ZI-FACTOR) tab., coated. coated, 500 mg: 3 pcs. • SUMAMOX granules for preparation. susp. for oral administration 200 mg/5 ml: vial. 50 ml • SUMAMED® FORTE powder for preparation. susp. for oral administration 200 mg/5 ml: vial. 29.295 g (35 ml) incl. on both sides. dosage spoon and/or dose. syringe • ZITHROCIN tab., coated. film-coated, 500 mg: 3 pcs. • SUMAMED® FORTE powder for preparation. susp. for oral administration 200 mg/5 ml: vial. 16.74 g (20 ml) included. on both sides. dosage spoon and/or dose. syringe • AZITRAL caps. 500 mg: 3, 6, 9 or 12 pcs. • SUMAZID caps. 250 mg: 6, 10, 12 or 20 pcs. • SUMAMED® powder for preparation. susp. for oral administration 100 mg/5 ml: vial. 50 ml 1 pc. included mern. spoon and/or dose. syringe • AZITHRUS powder for preparation. susp. for oral administration 100 mg/5 ml: cans 1 pc. included with a 2-sided dosing spoon or a dosing spoon and dispenser • AZITHRUS powder for preparation. susp. d/orally 200 mg: pack. 3 or 6 pcs. included with and without a glass • AZITHROMYCIN caps. 250 mg: 10 or 20 pcs. • ECOMED® (ECOMED) tab., coated. film coating, 250 mg: 6 pcs. • SUMAMED® caps. 250 mg: 6 pcs. • ZITHROCIN powder for preparation. susp. for oral administration 200 mg/5 ml: vial. 30 ml 1 pc. included with syringe and measuring spoon • AZITRAL caps. 250 mg: 6, 12, 18 or 24 pcs. • AZITHROMYCIN caps. 250 mg: 6 or 10 pcs. • SUMAMOX caps. 250 mg: 6 pcs. • AZITHRUS FORTE tab., coated. film coating, 500 mg: 3 or 6 pcs. • AZITHROX® caps. 250 mg: 6 pcs. • AZITHRUS® caps. 250 mg: 6 pcs. • SUMAMECIN caps. 250 mg: 6 or 10 pcs. • HEMOMYCIN lyophilisate for preparation. r-ra d/inf. 500 mg • HEMOMYCIN powder for preparation. susp. for oral administration 100 mg/5 ml: vial. 1 PC. included with measure spoon • AZIMYCIN tab., coated. film-coated, 500 mg: 3 or 6 pcs. • AZITHROMYCIN tab., coated. film-coated, 500 mg: 3 pcs. • HEMOMYCIN caps. 250 mg: 6 pcs. • ECOMED caps. 250 mg: 6 or 10 pcs. • AZITHRUS® powder for preparation. susp. d/orally 100 mg: pack. 3 or 6 pcs. included with or without a glass • AZITHRUS powder for preparation. susp. for oral administration 200 mg/5 ml: cans 1 pc. included with a 2-sided dosing spoon or a dosing spoon and dispenser • ZITROLID® (ZITROLID) caps. 250 mg: 6, 10, 60 or 100 pcs. • ZITROLID FORTE caps. 500 mg: 3 or 6 pcs. • ZETAMAX RETARD powder for preparation. susp. with deceleration release for oral administration 2 g: 1 pc. • SUMAKLID caps. 250 mg: 3 or 6 pcs. • HEMOMYCIN tab., coated. film-coated, 500 mg: 3 pcs. • AZIWOK caps. 250 mg: 6 pcs. • AZICID tab., coated. coated, 250 mg: 3 or 6 pcs. • AZITHROMYCIN caps. 250 mg: 6 pcs. • SAFOCID (SAFOCID) a set of tablets of three types: 4 pcs., including: tab. fluconazole 150 mg: 1 piece; tab. azithromycin, coating casing, 1 g: 1 piece; tab. secnidazole, coating casing, 1 g: 2 pcs. • SUMAMED® FORTE powder for preparation. susp. for oral administration 200 mg/5 ml: vial. 35.573 g (42.5 ml) incl. on both sides. dosage spoon and/or dose. syringe • SUMAMED® (SUMAMED®) tab., coated. film-coated, 125 mg: 6 pcs. • ZITHROCIN tab., coated. film-coated, 125 mg: 6 pcs. • AZIMYCIN tab., coated. film-coated, 250 mg: 3 or 6 pcs. • ZI-FACTOR caps. 250 mg: 6 or 10 pcs. • HEMOMYCIN powder for preparation. susp. for oral administration 200 mg/5 ml: vial. 1 PC. included with measure spoon
Buy Azithromycin capsules 250 mg No. 6 in pharmacies
Buy Azithromycin-OBL in pharmacies Azithromycin-OBL in the drug directory DOSAGE FORMS capsules 250mg
MANUFACTURERS Vertex (Russia)
GROUP Antibiotics - macrolides and azalides
COMPOSITION Active substance - azithromycin.
INTERNATIONAL NON-PROPENTED NAME Azithromycin
SYNONYMS Azivok, Azimicin, Azitral, Azitrox, Azithromycin, Azithromycin Zentiva, Azithromycin Forte, Azithromycin-Akos, AzitRus, AzitRus forte, Azicide, Vero-Azithromycin, Zetamax retard, Zi-Factor, Zimax, Zitrolide, Zitrolide forte, Zitrocin, Sumazid, Sumamed, Sumamed forte, Sumametsin, Sumamox, Sumatrolide Solutab, Hemomycin, Ecomed
PHARMACOLOGICAL ACTION Pharmacological action - antibacterial. Suppresses protein biosynthesis, slowing down the growth and reproduction of bacteria; at high concentrations, a bactericidal effect is possible. Stable in an acidic environment, lipophilic, quickly absorbed from the gastrointestinal tract. The maximum concentration is created after 2-3 hours, the half-life is 68 hours. Stable plasma levels are achieved after 5-7 days. Easily passes histohematic barriers and enters tissues. Concentrations in tissues and cells are 10-50 times higher than in plasma, and at the site of infection - 24-34% higher than in healthy tissues. A high level (antibacterial) remains in tissues for 5-7 days after the last injection. Excreted unchanged in bile (50%) and in urine (6%). The spectrum of action is wide and includes gram-positive (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, streptococci of groups C, F, G, Streptococcus viridans ), except for those resistant to erythromycin, and gram-negative (Haemophilus influenzae, Moraxella catarrhalis, Bordetella pertussis, Bordetella parapertussis, Campylobacter jejuni, Legionella pneumophila, Neisseria gonorrhoeae, Gardnerella vaginalis) microorganisms, anaerobes (Bacteroides bivius, Peptostreptococcus spp., Peptococcus, Clostridium perfringens) , chlamydia (Chlamydia trachomatis, Chlamydia pneumoniae), mycobacteria (Mycobacteria avium complex), mycoplasma (Mycoplasma pneumoniae), ureoplasma (Ureaplasma urealyticum), spirochetes (Treponema pallidum, Borrelia burgdorferi).
INDICATIONS FOR USE Infections of the upper and lower respiratory tract (streptococcal pharyngitis and tonsillitis, bacterial exacerbation of chronic obstructive pneumonia, interstitial and alveolar pneumonia, bacterial bronchitis), ENT organs (otitis media, laryngitis and sinusitis), genitourinary system (urethritis and cervicitis), skin and soft tissues (erysipelas, impetigo, secondary infected dermatoses), chronic stage of erythema migrans (Lyme disease).
CONTRAINDICATIONS Hypersensitivity to macrolides, severe liver dysfunction, pregnancy, lactation.
SIDE EFFECTS Nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea, melena, cholestatic jaundice, chest pain, palpitations, weakness, drowsiness, headache, dizziness, nephritis, vaginitis, candidiasis, neutropenia or neutrophilia, pseudomembranous colitis, photosensitivity , rash, angioedema, eosinophilia; in children, in addition, hyperkinesia, agitation, nervousness, insomnia, conjunctivitis.
INTERACTIONS Antacids containing aluminum or magnesium hydroxide reduce absorption and maximum concentrations.
METHOD OF APPLICATION AND DOSAGE Orally (1 hour before or 2 hours after meals), taken 1 time per day. Adults with infections of the upper and lower respiratory tract, infections of the skin and soft tissues - on the first day 0.5 g, from the 2nd to the 5th day - 0.25 g / day. Course dose - 1.5 g. For urogenital diseases - 1 g once; for Lyme disease - 1 g on the first day, from the 2nd to the 5th day - 500 mg (course dose - 3 g). Children over 12 months on the first day - 10 mg/kg, then 4 days - 5 mg/kg or 10 mg/kg per day for 3 days (course dose - 30 mg/kg); for Lyme disease on the first day - 20 mg/kg, from the 2nd to the 5th day - 10 mg/kg/day.
OVERDOSE No information available.
SPECIAL INSTRUCTIONS Use with caution in cases of severe dysfunction of the liver, kidneys, and cardiac arrhythmias. After discontinuation of treatment, hypersensitivity reactions may persist in some patients, which requires specific therapy under medical supervision.
STORAGE CONDITIONS List B. Store in a dry place, protected from light, at room temperature, out of the reach of children.
